Cargando…

DOCK4 Is a Platinum-Chemosensitive and Prognostic-Related Biomarker in Ovarian Cancer

Ovarian carcinoma (OV) is a lethal gynecological malignancy. Most OV patients develop resistance to platinum-based chemotherapy and recurrence. Peroxisome proliferator-activated receptors (PPARs) are the ligand activating transcription factor of the nuclear receptor superfamily. PPARs as important t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Qianqian, Zhong, Jie, Lu, Ping, Feng, Xiao, Han, Ying, Ling, Chenqi, Guo, Wenke, Zhou, Weijin, Yu, Fudong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878079/ https://www.ncbi.nlm.nih.gov/pubmed/33613670 http://dx.doi.org/10.1155/2021/6629842

Ejemplares similares

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer
por: Wang, Tianzhen, et al.
Publicado: (2019)

cis-platinum and ovarian carcinoma. In vitro chemosensitivity of cultured tumour cells from patients receiving high dose cis-platinum as first line treatment.
por: Wilson, A. P., et al.
Publicado: (1987)

High expression of TCN1 is a negative prognostic biomarker and can predict neoadjuvant chemosensitivity of colon cancer
por: Liu, Guang-jie, et al.
Publicado: (2020)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines
por: Sawers, L, et al.
Publicado: (2014)

Estrogens Counteract Platinum-Chemosensitivity by Modifying the Subcellular Localization of MDM4
por: Lucà, Rossella, et al.
Publicado: (2019)

miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer
por: Yu, Xiaotang, et al.
Publicado: (2020)

ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
por: Zhang, Yuqiang, et al.
Publicado: (2021)

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
por: Sassu, Carolina Maria, et al.
Publicado: (2021)

The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
por: Kim, Geon, et al.
Publicado: (2019)

Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis
por: Lai, Yu-Hsuan, et al.
Publicado: (2018)

Tumor metabolism regulating chemosensitivity in ovarian cancer
por: Han, Chae Young, et al.
Publicado: (2018)

A newly synthesized platinum-based compound (PBC-II) increases chemosensitivity of HeLa ovarian cancer cells via inhibition of autophagy
por: Alotaibi, Moureq Rashed, et al.
Publicado: (2019)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

A seven-gene prognostic model for platinum-treated ovarian carcinomas
por: Sabatier, R, et al.
Publicado: (2011)

Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis
por: da Costa, Alexandre André Balieiro Anastácio, et al.
Publicado: (2019)

The effects of ERCC1 expression levels on the chemosensitivity of gastric cancer cells to platinum agents and survival in gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy
por: LIU, YONG-PING, et al.
Publicado: (2013)

Biomarking and Induction of Apoptosis in Ovarian Cancer Using Bifunctional Polyethyleneimine-Caged Platinum Nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Annexin A3 Is a Potential Predictor of Platinum Resistance in Epithelial Ovarian Cancer Patients in a Prospective Cohort
por: Jin, Ying, et al.
Publicado: (2015)

Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers
por: Atallah, Ghofraan Abdulsalam, et al.
Publicado: (2023)

Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells
por: Xu, Lei, et al.
Publicado: (2021)

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
por: Zhang, Hongqin, et al.
Publicado: (2022)

Corrigendum: Biomarking and induction of apoptosis in ovarian cancer using bifunctional polyethyleneimine-caged platinum nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer
por: Li, Guoping, et al.
Publicado: (2020)

Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer
por: Dionísio de Sousa, Isabel J., et al.
Publicado: (2020)

Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer
por: Liu, Jiao, et al.
Publicado: (2023)

Effects of trans-(±)-kusunokinin on chemosensitive and chemoresistant ovarian cancer cells
por: Mad-Adam, Nadeeya, et al.
Publicado: (2022)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Inhibition LC3B can increase chemosensitivity of ovarian cancer cells
por: Tang, Jing, et al.
Publicado: (2019)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
por: Compadre, Amanda J., et al.
Publicado: (2023)

A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy.
por: Wilson, J. K., et al.
Publicado: (1990)

Association of p53 and mitochondrial gene with chemosensitization by metformin in ovarian cancer
por: Wei, De-Hua, et al.
Publicado: (2017)

PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
por: Gentric, Géraldine, et al.
Publicado: (2019)

Intracellular optical doppler phenotypes of chemosensitivity in human epithelial ovarian cancer
por: Li, Zhe, et al.
Publicado: (2020)

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
por: Crean-Tate, Katie K., et al.
Publicado: (2021)

Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer
por: Liu, Bo-lin, et al.
Publicado: (2014)

MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma
por: Liu, Wei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j9vrqs65qvqljk2718duue5oa1